Trials / Completed
CompletedNCT06812585
The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- German University in Cairo · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This pilot study aims to investigate the tolerability and feasibility of using metformin as an adjuvant treatment for RRMS. Also, it aims to evaluate the preliminary evidence of its efficacy by analyzing outcomes related to immunology, clinical manifestations, and radiological findings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin (Cidophage®) | Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes. |
| OTHER | Usual Care | Active Comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2023-05-30
- Completion
- 2025-01-30
- First posted
- 2025-02-06
- Last updated
- 2025-02-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06812585. Inclusion in this directory is not an endorsement.